What's your strategy?
I try to position 12-15 value, special situation, growth stocks
for my clients in order to provide another asset class in their overall
investment picture. I'm looking for value stocks that have the potential
or a catalyst to become growth stocks. Value managers want to buy $1.00
for 50 cents and sell it for 80 cents to $1.00. I'm looking for $1.00
for 50 cents that can end up being a growth stock that will sell at
$2.00 or $3.00. Many of these are what I call "onion stocks".
What are onion stocks?
These are stocks where you need to peel off a lot of layers over quarters
or even years to realize something that a lot of people want down the
road. Those layers can be debt restructurings, lawsuits, asset sales,
change in management or new product introductions down the road, etc.
I try to position my portfolios and equities so they aren't reliant
on the market going up, or the economy getting better, in order to outperform.
And that's what we've seen. The last few years with the market down
50 percent, I avoided telecommunication and other overvalued stocks
and got into the Mattel's at 10 and the Philip Morris' in the low 20's
-- stocks where I didn't think the market made much difference.
You mix larger cap stocks with small caps?
Yes. I'm a big believer in the "dead money" theory, that if
investors perceive something to be dead money for years they will sell
it no matter how cheap. I don't believe the litigation of Philip Morris
-- the worry of bankruptcy -- was as big a factor as the feeling that
there were going to be years and years and years of lawsuits and the
stock was not going to go anywhere. I understand the tobacco situation
very closely, so I was comfortable with the litigation. I was in oil
stocks when oil was at $12 a barrel and every oil analyst and every
industry analyst was telling us that oil was dead and wasn't going anywhere
for many years -- that there was an overcapacity. That's when I say
fine, but I'm buying these stocks at or below book value and I'll wait.
They're often but not always small caps.
I have a number of stocks at or under cash value, with no debt. I try
to stay a little bit lighter on the debt, unless I really know what's
going on. I bought Mattel when they had no CEO, when The Learning Company
was draining money from them, but I had to have a leap of faith that
the board of directors and management were going to make changes. I
asked: If it all blows up, what can I sell the assets for? What can
I sell Fisher-Price, Hot Wheels and Barbie for in a fire sale? And the
numbers I came up with were about $7-$8 a share, so I was happy taking
a position at $10 a share. I sold it a year or so later at $21.
Why 12-15 stocks, and how do you manage risk, given your concentrated
portfolio?
Everything I've seen in my research shows there's a diminishing marginal
return that takes place when you get above 20 stocks. In other words,
expanding a portfolio to 50 or 100 stocks does almost nothing for performance.
It doesn't minimize downside risk at all. All you're doing is resigning
yourself to tracking whatever index of stocks are in your portfolio.
It just makes the job easier for money managers to go play golf. I think
somebody said if you have two mutual funds in your portfolio you're
over-diversified. I'm not saying that 12-15 stocks should be in your
entire investment portfolio. I'm saying in the 15 percent of your invested
assets that I recommend be in this area, I'm going to have 15 stocks.
Which equates to about 1 percent of your entire portfolio per position.
I try to have all my 12-15 stocks non-correlated, so I'm not overexposed
to any one industry. I like all of them to be undervalued using a number
of valuation methodologies. You really have to go far beyond the P/E,
cash flow, EBITDA kind of common valuation methodologies, and I think
it takes a lot of time understanding them for each industry and each
stock. A lot of valuation is multi-layered and I think the mistakes
that are made are sticking to one particular methodology.
What additional methodologies do you use?
Let's look at Tenet Healthcare (THC), for example, here in Santa Barbara,
which I had been purchasing in the mid-to-high teens in the late 1990's
and sold it at $30 or so. Later, when it was at $50 or $60 the market
was really only looking at the P/E. In hindsight they were charging
clients too much, pushing earnings numbers higher. If you were looking
at another valuation parameter -- the price you're paying in the market
cap per hospital bed -- you were paying $1 million per bed. Any rational
investor would just run away from something like that. So, that's why
I avoided it. It is now in the mid to low teens where the valuations
are more reasonable.
On the other hand, for instance, one of my favorite stocks right now
is UnitedGlobalCom (UCOMA), which owns almost 70 percent of the largest
cable company in Europe, and John Malone and Liberty Media own 75 percent
of UnitedGlobalCom. But too much emphasis was placed on current cash
flows before the debt restructuring, indicating the stock was overvalued,
and not enough emphasis was on what the actual price reflected per user.
They were just giving the stock away, and using that valuation metric.
I though it was a tremendous buy. UnitedGlobalCom is an example of my
ideal investment.
How so?
I want to find a stock where the downside is very small over time if
everything goes wrong. UnitedGlobalCom had this big debt restructuring
situation in Europe and the stock was down to $1.50 a share, but what
the market wasn't looking at was that they had assets -- cable assets
-- that they owned in full or in part in Chili, one of the strongest
countries in South America, as well as in Argentina, New Zealand and
Australia. Any normalized valuation of those properties would give you
$1-$1.50 a share.
So, I'm basically buying this company at $1.50 and the downside is almost
negligible. Now, Europe could blow up and all those 8 million subscribers
and the majority value of this company could go away, and I'd still
be left with minimum downside. But if it works, which I felt it would,
I'd have a big winner, and it is proving to work. They've gotten through
the restructuring, they peeled off the layers of the onion, taken $11
billion in debt and reduced it to $3.5 billion in bank debt. The stock
is now at about $4 with a lot of upside over the next several years
if growth continues with cable and Internet in Europe. So, in this case,
I'm going to be holding it, hoping to get somewhere between a 5 and
10 bagger. This doesn't mean I am only looking for the 10 bagger; generally,
I look for 40 to 60 percent moves in my stocks.
How do you find these stocks? Where do you get your ideas from?
I think this is maybe one of the most important aspects of what I bring
to the table and what helps manage risk. I think your idea flow and
the quality of idea flow is a very important factor in managing risk
because a lot of investors stay in fully valued stocks hoping to get
a little bit more out of them because they don't have other places to
go that are very compelling. So having a lot of good ideas to choose
from in any market is key. I have developed over my 16 years in the
business a handful of colleagues who I believe share the same valuation
methodologies, are very astute, and we share ideas all of the time.
This is just one aspect of it. I will get ideas from TV shows, magazines,
newsletters I'm involved with. That on top of the investment firms whose
research I have access to - Salomon Smith Barney or Bear Stearns, or
what have you. The important factor is that I am the final decision
maker on all the ideas.
What themes would you say you're playing and what are a couple of
stocks that fit into those themes?
As mentioned, I'm buying stocks that are under cash value with little
or no debt. Some of these are simply stocks where you just have to be
there. I don't have a crystal ball, I don't know if they're going to
make it, but I know they're going to have years and years and years
of staying power to get through to the next product cycle.
For instance, Palm (PALM) is interesting to me because it's just about
at cash value with no debt at $9 a share. I don't know if the next product
cycle is going to be in six months or three or four years, but these
are the kinds of companies I think can see through to the next cycle.
When a cycle hits, multiples kick in and these stocks can be two, three
or four times higher, if that happens.
That's why ValueClick (VCLK) is another one of mine I like. With $3
a share in cash and no debt, I was buying it at $2 a share. They're
actually making money, and the stock is now at $4.00. They are in Internet
advertising. These are things that are going to be with us for a long
period of time.
I don't like the computer industry, but was buying SanDisk (SNDK) in
the low teens with $5/share in cash net of debt. They make the flashcards
for digital cameras and cell phones. That's an area that's just going
to keep growing for years and years, and I want to be a part of that.
Sometimes hidden assets compel me to own stocks. When JC Penney (JCP)
gets into the low to mid teens I usually buy it. Not for the 1,900 JC
Penney stores, but for the 2,900 Eckerd drug stores they own, which
in my view are worth as much as the stock at those levels.
As I've said, I always like some cushion down there so if everything
goes wrong I've got some asset that's worth a lot of money. I like Metro-Goldwyn-Mayer
Inc (MGM) because their film library could be worth more than the current
stock price. I'm looking at Midas Muffler (MDS). They're going through
a restructuring, got rid of their distribution plants, but the value
of their real estate could be worth well above the current stock price.
Those kinds of things. But I understand, there has to be some catalyst,
something to get the earnings growing, or these are going to be dead
for a long period of time.
These are companies I would have thought were large caps but have
come down into almost small cap land.
They've been killed. One of my favorite stocks, very controversial,
is Vector Tobacco (VGR). They're introducing a nicotine-free cigarette,
which has been out for the last couple of months in seven East coast
states. They've genetically blocked the production of nicotine in the
root. It pays about a 14 percent dividend here, but they are paying
the dividend out of capital as income is being used to introduce new
products, but the underlying discount cigarette business is what keeps
me with this company. Vector is exempt from the MSA payments to the
States, so their cash flows are very substantial because of this advantage
which helps fund these new products. The first product they had called
Omni did not work and it cost them a lot of money, and the stock got
hammered from the $30s and low $40s all the way back down to $10-$12.
Down here I think the value of the underlying business is worth far
more than the current stock price. I also look and see what Gabelli's
doing and what Ichan's doing. Ichan owns 20 percent of Vector. There are
certain guys out there that I respect, I like their methodologies, so
I'll look and follow things they do and may get involved with what they're
doing. I'll run the numbers and figure out what the kind of potential
upside is if things work out and then marry that with the downside risk
and see if that makes sense. With Vector, if Quest is successful, the
upside is substantial and the underlying discount business supports
the current valuation in my opinion.
What are your thoughts on a more macro level and how does that impact
your investing?
I don't disregard the macro level, but it doesn't get in the way of
a lot of what I do. Just like I said, in 2000 I thought the market was
absurdly overpriced and thought it was at a risk of falling 50 percent,
certainly the Nasdaq, yet I was fully invested. Right now, I've been
looking for a war rally and I think that could continue. But my outlook
over the next two to three years is very bleak. We could muddle through
it, but the risk is too great. When you look at other countries, it's
easy to see bubbles, it's easy to see Argentina, Mexico in 1995 and
Japan 10-12 years ago and say they're out of control. But when you're
inside one, it's hard to see the bubble. We're talking about huge consumer,
corporate, and government debt levels -- state budget deficit problems.
I see a dollar at risk and I see some real problems like interest rates
going up perhaps if the dollar falls. I see real estate pulling back
and the bottom line is I see consumers who have been spending out of
their minds for the last number of years, using their homes as ATM machines,
pulling back. That could cause serious problems and I think the Dow
could be at risk of going down 40 percent or more from here -- to the
4,000 area. Having said that, it's just going to be a matter of finding
more and more opportunities.
|
 |
11
Micro-Caps Worth Watching
A
Message From Our Sponsor: |
By
John Dutton, President, JM Dutton & Associates, LLC
As
one of the largest independent equity research firms
in the U.S., Dutton & Associates is helping investors
gain high-quality fundamental research on good companies.
Many of these companies had little or no research
coverage prior to us, and as a result have been under
Wall Street's proverbial "radar screen"
and trading at prices well below intrinsic value.
Our
program of independent research minus any investment
banking or brokerage constraints involves a full year
of coverage, with an initial report, three quarterly
reports, and research notes in between the quarters.
The
following are companies we've reported on within the
last several weeks, whose reports on our site at www.jmdutton.com
may be of interest to you:
First
Cash Financial Strong Buy Rating Maintained In Update
Report
April
21, 2003. First Cash (FCFS) reported record revenue
($118.8 million) and earnings ($10.9 million) for
FY 2002. The 7.6% growth in 2002 revenue resulted
from a 4.5% increase in same-store sales (net of jewelry
scrap sales) and revenue from 38 new stores opened
in 2002. The 39% net income gain is impressive - costs
for the new stores were expensed during the year.
First Cash maintains a well-planned expansion program,
with FY 2003 to add 40 to 50 new stores. Also, improvement
in its balance sheet ratios and income statement margins
was quite impressive. First Cash projected fully diluted
earnings per share of $0.34 to $0.35 for the first
quarter of 2003 and reconfirmed its previous 2003
estimate of EPS in a range of $1.28 to $1.31 per FD
share. We maintain our 12 month price target of $16.25
based on an expected low-end range of its P/E of 13.5x.
Neurobiological
Technologies Buy Rating Maintained In Update Report
April 16, 2003. Clinical data for Neurobiological
Technologies' lead product for Alzheimer's disease,
Memantine, continues to support a high probability
of FDA approval. Results of two separate studies have
been recently presented at the American Medical Directors
Association annual meeting and at the prestigious
American Academy of Neurology Annual Meeting held
in Honolulu, Hawaii in early April. NTII's US marketing
partner, Forest Laboratories, remains optimistic the
FDA will issue an action letter regarding the Memantine
submission by the end of 2003. Forest Laboratories'
pivotal diabetic neuropathy trial is undergoing data
analysis. The last patient was out of follow up in
late December and headline study results are expected
before the end of April 2003. Paul Freiman, NTII CEO,
noted on April 8 that the Company is preparing to
begin two Phase III trials during the current quarter
for the use of Xerecept in the treatment of peritumoral
brain swelling.
Aastrom
Biosciences Rating Raised to Strong Speculative Buy
April 10, 2003. Aastrom is experiencing increasing
commercial sales of its cell production products.
Installations of the Company's AastromReplicell(tm)System
for cell replication; the DC-I dendritic cell product
for fusion and transfection cell-based therapeutics;
the DCV-I antigen-loaded dendritic cell complex; and
DCV-II, peptide-loaded dendritic cells at academic
research and commercial cancer vaccine development
organizations in Europe increased by 20% in the December
quarter with its 15 installations of the AastromReplicell
System in Europe and the US. On April 1, Aastrom announced
the results of a study in which the Company's Tissue
Repair Cells were used to safely generate bone in
a girl with the genetic bone disease, hypophosphatasia.
Our rationale for the rating upgrade is underpinned
by the Company's progress, the recent infusion of
capital and, in our view, the misguided selling pressure
in the Company's shares as a result of investor confusion
and concern over the Company's listing status.
CytoGenix
Speculative Buy Rating Maintained
April 02, 2003. CytoGenix has added Dr. Cy Stein,
a pioneer in the field of the molecular biology of
oligonucleotide intervention, to its Board of Directors.
CytoGenix continues to add to its base of intellectual
property in ssDNA and RNA directed technologies. It
develops products that exploit its antisense and DNA
enzymatic systems technology, using its proprietary
ssDNA expression system to down-regulate proteins
associated with viral replication of herpes, shingles
or HPV and inflammatory processes such as psoriasis
and male pattern baldness. CytoGenix continues to
rely on private equity placements to fund operations,
and it will be imperative for the Company to raise
additional funding in order to pursue its current
business plan and operations model. The Company is
an unexploited, and still undiscovered company with
exciting new technology and carries the inherent risks
of a microcap biotechnology company with very limited
financial resources. The shares are rated a Speculative
Buy.
Buy
Rating Issued For Travelzoo
March 27, 2003. Travelzoo Inc. is an on-line publisher
of advertisements for travel-providing companies.
On its Travelzoo(r) website, www.travelzoo.com, Travelzoo
publishes advertisements supplied by its client list
of 200 travel-providing companies. This site enjoys
high traffic from approximately 4.6 million travel
consumers. The Company also publishes the Travelzoo
Top 20(tm) e-mail newsletter, top20.travelzoo.com,
which is a weekly listing of 20 top money-saving travel
deals sent to four million subscribers. We believe
the current market valuation of Travelzoo does not
reflect its excellent above-average financial history,
its experienced management in the Internet advertising
market place, nor its potential for revenue growth
in the coming years. Future revenue increases will
be two-fold as: (1) the database of subscribers increases
and (2) the number of advertising clients increases.
Revenues were $.9 million in 1999, forecast to be
$16.1 million in 2003, while comparable period net
income has gone from $.1 million to a forecast $2.6
million in 2003. The Company has no debt.
Nymox
Buy Rating Issued
March 26, 2003. Nymox (NYMX) is a young biopharmaceutical
company that already has products approved for sale.
Its AlzheimAlertTM, a urine test to aid in the diagnosis
of early stage Alzheimer's disease, and its NicAlertTM
urine and NicoMeterTM saliva tests for monitoring
exposure to nicotine, are both first-to-market semi-quantitative
tests for their respective marketplaces. These products
are in the very early stages of commercial launch.
The Company's core technologies, novel neuronal proteins
and particle valence medicated immunoassays, allows
the Company to develop a range of future products.
Its particle valence immunoassay technology can be
"ported" to a variety of conditions where
point-of-care quantitative tests would be beneficial,
such as glucose and cholesterol monitoring. The Company's
technology portfolio is sufficiently robust to allow
significant partnering or out-licensing opportunities
without the risk of "giving away the store."
Revenues are forecast to grow to US$2.1 million in
2004 from $0.8 million in 2003. EPS are forecast at
$(0.14) for 2002 reducing to $(0.07) in 2004.
LESCO
Speculative Buy Rating Issued For Largest Supplier
To Professional Lawn Care And Golf Course Market
March 12, 2003. LESCO (LSCO) is the largest supplier
to the highly fragmented U.S. professional lawn care
and golf course market. It is the industry's largest
vertically integrated supplier, offering the most
extensive product line, with operations mainly in
the Eastern US, primarily in Florida and the Washington,
D.C.-Boston corridor. LESCO has substantial opportunity
for geographic expansion. A new management team is
refocusing LESCO's use of investment capital on expanding
and restructuring the Company's historically profitable
sales system while divesting less profitable businesses
and reining in non-sales overhead costs. Renewed sales
momentum should become evident during the spring 2003
season, with sales in 2003, 2004, and 2005 estimated
to rise to $547 million, $588 million, and $641million
respectively. EPS are estimated at $.72 in 2003, rising
to $1.21 in 2005, and to achieve 20% annual growth
from 2005 through 2008.
Medicsight
Buy Rating Maintained In Update Report
March 10, 2003. With its first Lifesyne(tm) scanning
center operational in London, Medicsight's (MSHT)
Medicsight(tm) system is now positioned to become
a "brand identity" in cost-effective scanning
and early disease detection for chronic heart disease
and cancer. Lifesyne Centers will scan referred "at-risk"
individuals for the highest mortality diseases namely,
lung and colorectal cancers, and coronary heart disease.
Medicsight's image processing system was reported
capable of identifying 100% of isolated pulmonary
nodules from CT scans, and uses London's first GE
advanced Lightspeed 16-detector multi-slice CT scanner.
In its first 30 days of operation, the center performed
130 scans on high-risk patients for coronary heart
disease and lung cancer, detecting notable and significant
findings in 18% of these patients. Two other Lifesyne
centers are expected to open in London during early
2003. In FY2004, Company revenues are estimated at
US$14.7 million with EPS of $0.01. The Company has
filed for an AMEX listing.
Cap
Rock Q4 & 2002 Net Income Soars; EPS For 2002
Hits $6.75
April 15, 2003. Cap Rock Energy (RKE) reported a stronger
than expected 4th quarter net income of $1.0 million
due to a successful rate increase and the recognition
and recovery of previous power costs. They reported
2002 net income of $8.7 million or $6.75 per share.
We continue to rate these shares a Strong Buy, with
RKE selling at $13.65 representing a P/E of 3.8x our
current estimate of 2003 EPS of $3.65 (estimate under
review).
Comments
on Vita's 2002 Fourth Quarter Results
March 19, 2003. Vita's (VSF) Q4 showed exceptionally
strong sales and profitability growth in the new salmon
and salad dressing products. Total net sales of $14.7
million were 20% higher than Q4 2001 but gross profit
was up by only 7%. SG&A increased by 14% which
was a fairly positive result considering (a) the one
time auditing fees of $65,000 related to the Halifax
transaction and (b) the heavy slotting fees and demo
costs totaling $144,000 that were incurred during
the introduction of Virginia Brands new salad dressing
products to Vita's chain store customers. The notable
performance of new products has positive long-term
implications, as Vita's internal growth is dependent
on the development and introduction of new products.
We continue to rate Vita Food as a Strong Buy.
Deckers
Outdoor Corporation Reports Strong Operating Performance
In 2002 Q4
March 07, 2003. Deckers Outdoor Corporation reported
an exceptionally strong operating performance in the
Company's 2002 fourth quarter. Teva sales were up
by the very impressive rate of 42% to $10.7 million
from $7.56 million in the last quarter of 2001. The
extension of the Teva line to include closed-toe styles
of rugged outdoor footwear is reducing the seasonal
imbalance. Nearly all of the $3.14 million increase
in Teva sales in the fourth quarter was in the new
closed-toe products. The Company anticipates that
within three to five years, closed shoes will account
for 30% of Teva's sales. Teva sales for the year 2002
were $65.1 million up 6.3% year over year. The closed-toe
rugged outdoor sports footwear market is about $2.3
billion compared to $355 million for sport sandals.
Considering the Teva acquisition and the sales momentum
now apparent in all three product brands, Deckers'
stock should attract attention in the coming year.
Management's current guidance for 2003 diluted earning
per share is a range of $.41 to $.46. We continue
to rate the common stock of Deckers Outdoor Corporation
as a Buy.
Trinity
Biotech Strong Buy Rating Maintained and Target Price
Raised
April
07, 2003. The New York Times carried an interesting
article on Sunday, April 6, titled "Tech and
Health Care Shares Become Silk Purses." It began:
"The relatively few stock funds that eked out
small gains in a generally money-losing first quarter
tended to own health care and technology stocks,"
and mentioned that winning health care stocks included
Amgen (up 19.1%) and Forest Laboratories (up 9.9%).
We note that on a relative as well as absolute basis,
Trinity Biotech's (TRIB) recent performance has been
extraordinary, as it has more than doubled since our
basic report of January 27. Since the initial report,
our confidence in Trinity's fundamentals has increased
incrementally-- due to the better than expected fourth
quarter and the apparent success management is having
assimilating recent acquisitions. In March, Trinity
completed the submission of its PMA to the FDA for
its 10-minute test for HIV that is performed on a
drop of whole blood, plasma or serum. As discussed
previously, this has the potential to become Trinity's
single largest product. We have decided it is appropriate
to maintain our Strong Buy rating while raising our
12-month target from $2.75 to $3.25.
We
invite you to view our full coverage list and read
our reports at www.jmdutton.com
|
|
|